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Heart failure with preserved ejection fraction (HFpEF) is now the dominant form of heart
failure and one for which no efficacious therapies exist. Obesity and lipid mishandling greatly
contribute to HFpEF. However, molecular mechanism(s) governing metabolic alterations and
perturbations in lipid homeostasis in HFpEF are largely unknown. Here, we report that car-
diomyocyte steatosis in HFpEF is coupled with increases in the activity of the transcription
factor FoxO1 (Forkhead box protein O1). FoxO1 depletion, as well as over-expression of the
Xbp1s (spliced form of the X-box-binding protein 1) arm of the UPR (unfolded protein
response) in cardiomyocytes each ameliorates the HFpEF phenotype in mice and reduces
myocardial lipid accumulation. Mechanistically, forced expression of Xbp1s in cardiomyocytes
triggers ubiquitination and proteasomal degradation of FoxO1 which occurs, in large part,
through activation of the E3 ubiquitin ligase STUB1 (STIP1 homology and U-box-containing
protein 1) a novel and direct transcriptional target of Xbp1s. Our findings uncover the Xbp1s-
FoxO1 axis as a pivotal mechanism in the pathogenesis of cardiometabolic HFpEF and unveil
previously unrecognized mechanisms whereby the UPR governs metabolic alterations in
cardiomyocytes.
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Heart failure with preserved ejection fraction (HFpEF) isnow the most prevalent form of HF worldwide1–3. Instriking contrast with the other major form of HF—HF
with reduced ejection fraction, HFrEF—the incidence and pre-
valence of HFpEF have increased steadily over the last decade. As
of today, more than two-thirds of patients with HF over 65 years
of age suffer from the clinical syndrome of HFpEF3. Despite the
enormity of the problem, efficacious treatment options for these
millions of individuals are lacking4.
Limited understanding of pathophysiological mechanisms
underlying HFpEF is a prominent reason for the failure of clinical
trials thus far. HFpEF is a heterogeneous syndrome and not all
patients with HFpEF harbor the same predisposing conditions4.
However, the vast majority of them present with obesity and
metabolic syndrome5–8. Obesity increases the risk of HFpEF over
HFrEF and is associated with worsening of functional parameters
in HFpEF6. Indeed, elements of metabolic alteration have been
identified as crucial pathophysiological drivers of HFpEF in both
preclinical models and clinical studies5,9,10. Despite the well-
recognized association between obesity and HFpEF, mechanistic
elements governing the excess lipid accumulation in cardiomyo-
cytes—i.e. cardiac lipid overload—are poorly understood.
Disruption of endoplasmic reticulum (ER) homeostasis—also
known as ER stress—is a common feature in disease-stressed
cardiomyocytes11. ER stress triggers the unfolded protein response
(UPR), a multidimensional, adaptive signaling pathway capable of
mitigating stress under many conditions. Despite the name,
stresses other than unfolded proteins can activate the UPR. Cur-
rent evidence points to a clear association between the UPR and
hallmarks of metabolic syndrome: obesity and dyslipidemia12.
Indeed, either prolonged dysregulation of lipid synthesis or failure
of UPR activation to resolve insults can disrupt the homeostatic ER
environment and promote disease development13,14.
In mammals, the UPR involves three ER transmembrane
protein sensors: IRE1α (inositol-requiring kinase 1α), PERK
(PKR-like endoplasmic reticulum kinase), and ATF6 (activating
transcription factor 6). Differential roles of the individual UPR
transducers have been proposed. The IRE1α pathway is the most
highly conserved branch of the UPR. Upon ER stress, IRE1α
initiates the unconventional splicing of mRNA encoding Xbp1
(X-box–binding protein 1) to generate spliced Xbp1 (Xbp1s), a
powerful transcription factor involved in many cellular functions
essential to stress responsiveness. We described a cardioprotective
role of Xbp1s in HFpEF, providing evidence of IRE1α/Xbp1s
dysregulation in cardiomyocyte function in both experimental
and clinical HFpEF9. Across the spectrum of cardiovascular dis-
eases, suppression of the IRE1α/Xbp1s arm of the UPR is an
alteration unique to HFpEF. Indeed, restoring Xbp1s in HFpEF
cardiomyocytes substantially ameliorates the syndrome in
mice9,10. Looking forward, how disruption of the UPR con-
tributes to lipotoxic alterations in cardiomyocytes and cardio-
metabolic disease is poorly characterized, and mechanisms
whereby Xbp1s ameliorates the HFpEF phenotype remain elusive.
Hence, we set out to define and manipulate mechanisms down-
stream of Xbp1s in cardiometabolic HFpEF and decipher its
cardioprotective actions.
Here, we show that myocardial lipid accumulation and cardiac
metabolic alterations in HFpEF are coupled with increases in the
abundance and activity of FoxO1 (Forkhead box protein O1), a
conserved transcription factor involved in cell metabolism.
FoxO1 governs lipid accumulation in cardiomyocytes, and over-
expression of Xbp1s triggers FoxO1 ubiquitination and protea-
somal degradation. Using gain- and loss-of-function approaches
we demonstrate that genetic deletion of FoxO1, as well as Xbp1s
overexpression, in cardiomyocytes each ameliorates the HFpEF
phenotype and reduces cardiac steatosis. Finally, we identify the
E3 ubiquitin ligase STUB1 (STIP1 homology and U-Box-
containing protein 1) as a novel and direct transcriptional tar-
get of Xbp1s implicated in Xbp1s-dependent degradation of
FoxO1 in cardiomyocytes. These findings link UPR alterations
with metabolic dysregulation in HFpEF, unveiling the Xbp1s-
FoxO1 axis as a critical mechanism in the pathogenesis of lipid
abnormalities in cardiomyocytes.
Results
Xbp1s reduces myocardial lipid accumulation in HFpEF. We
have shown previously that a murine model of HFpEF displays
features of cardiometabolic disease9,10. As expected, cardiac tissue
samples from HFpEF mice manifest a significant increase in Oil
Red O staining for neutral lipids (Supplementary Fig. 1a) as well
as activation of a lipogenic gene program (Supplementary Fig. 1b)
in the absence of significant changes in the expression of genes
involved in lipid oxidation (Supplementary Fig. 1c). Importantly,
similar accumulation of neutral lipids and increased transcript
abundance of lipogenic genes were detected in cardiomyocytes
(adult murine ventricular myocytes—AMVMs) isolated from
HFpEF hearts (Supplementary Figure 1d, e).
In murine and human HFpEF, downregulation of Xbp1s in
cardiomyocytes correlates with the development of the syndrome,
and cardiomyocyte-specific overexpression of Xbp1s is sufficient to
ameliorate the HFpEF phenotype9 (Supplementary Fig. 2a–e and
Supplementary Table 1). In light of this, we next set out to test for a
causal role of Xbp1s-associated protective effects. Qualitative staining
for neutral lipids as well as measurement of triglyceride content
revealed significant reduction of lipid accumulation in the hearts of
cardiomyocyte-specific Xbp1s-overexpressing transgenic mice
(XBP1s TG) despite exposure to HFpEF-inducing conditions (Fig. 1a,
b). Xbp1s overexpression was also associated with suppression of
lipid storage/transport gene expression (Supplementary Fig. 2f).
Importantly, Xbp1s overexpression in XBP1s TG hearts, as well as in
neonatal rat ventricular myocytes (NRVMs) using a recombinant
adenovirus driving expression of Xbp1s (AdXbp1s; Supplementary
Fig. 2g, h) did not alter basal mitochondrial lipid oxidation
(Supplementary Fig. 2i, j), suggesting that reduced lipid levels in
Xbp1s-overexpressing cardiomyocytes are likely not the result of
increased lipid utilization. Collectively, these results suggest that
Xbp1s regulates cardiomyocyte lipid content in HFpEF.
Xbp1s promotes FoxO1 protein degradation in cardiomyo-
cytes. Prior studies in the liver have revealed a role for Xbp1s in
regulating metabolism by modulating FoxO1 activity15. In addi-
tion, we and others have described previously a critical role of
FoxO1 in regulating lipid homeostasis16,17. Based on this, we
hypothesized an interplay between Xbp1s and FoxO1 transcrip-
tion factors occurs in the heart. Notably, in the hearts of Xbp1s
TG mice, we detected a significant reduction in FoxO1 protein
(Fig. 1c, d), whereas FoxO1 mRNA levels under both control
(CTR) and HFpEF conditions remained unchanged (Supple-
mentary Fig. 2k). These data suggest Xbp1s-dependent post-
transcriptional regulation of steady-state FoxO1 protein levels.
FoxO1 protein stability is known to be regulated by
proteasomal degradation18. To test for this in cardiomyocytes,
NRVMs were infected with AdXbp1s or adenovirus encoding
green fluorescent protein (AdGFP) in the presence or absence of
the proteasome inhibitor MG132. In NRVMs, Xbp1s over-
expression increased FoxO1 polyubiquitination (Supplementary
Fig. 3a) and reduced FoxO1 protein levels (Fig. 1e, f) and nuclear
localization (Fig. 1g, h) without affecting its transcript levels
(Supplementary Fig. 2l). Xbp1s-induced degradation of FoxO1
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protein was partially rescued by MG132 proteasome inhibition
(Fig. 1i). Importantly, protein levels of the other major FoxO
family member in cardiomyocytes, FoxO3, were not affected by
XBP1s overexpression (Fig. 1i, j). In aggregate, these findings
establish Xbp1s as a regulator of FoxO1 protein stability in a
proteasome-dependent manner.
FoxO1 promotes lipid accumulation in HFpEF cardiomyo-
cytes. Our preclinical two-hit model of HFpEF stems from the
combination of metabolic alterations (exposure to high-fat diet;
HFD) and endothelial dysfunction-driven hypertension (modeled
using the inhibitor of constitutive nitric oxide synthases N[w]-
















































































































































































































NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-21931-9 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:1684 | https://doi.org/10.1038/s41467-021-21931-9 | www.nature.com/naturecommunications 3
numerous features of clinical HFpEF9. Indeed, single hits, either
HFD or L-NAME alone, do not elicit HFpEF in mice9. To eval-
uate FoxO1 activation in the setting of these different stresses, we
assessed its nuclear localization. Nuclear fractionation of left
ventricular (LV) samples revealed no increase in nuclear FoxO1
in animals treated with L-NAME alone (Supplementary Fig. 4a).
Furthermore, short-term HFD was sufficient to increase nuclear
FoxO1 levels (Supplementary Fig. 4a). HFpEF hearts manifested a
threefold increase in FoxO1 nuclear localization when compared
with regular diet CTR mice and twofold over HFD alone-treated
mice (Fig. 2a, b and Supplementary Fig. 4a). A similar increase in
nuclear localization of FoxO1 was observed in AMVMs isolated
from HFpEF mice, confirming that these changes are
cardiomyocyte-specific (Fig. 2c, d). We also observed an increase
in the FoxO1-dependent transcriptional program in both HFpEF
LV and AMVM samples (Fig. 2e, f). These data indicate that
FoxO1 activity is increased in cardiomyocytes in the setting of
HFpEF.
To determine the specific role of FoxO1 in promoting lipid
accumulation in cardiomyocytes, we treated NRVMs with bovine
serum albumin (BSA)/oleate mono-unsaturated fatty acid (FA)
complex. Twenty-four and 48 hours of treatment were sufficient
to induce lipid accumulation (Supplementary Fig. 4b) without
significantly impacting cardiomyocyte viability (Supplementary
Fig. 4c). In parallel, FoxO1 transcript levels were increased in
NRVMs as early as six hours after BSA/Oleate treatment
(Supplementary Fig. 4d). To test for a causal link between
increased FoxO1 levels and lipid accumulation in cardiomyocytes,
we employed both FoxO1 gain- and loss-of-function approaches.
As expected, infection of NRVMs with recombinant adenovirus
driving expression of a constitutively active FoxO1 mutant
(AdcaFoxO1) resulted in a robust increase in FoxO1 transcript
and its gene-dependent transcriptional program, whereas control
infection with AdGFP had no effect (Supplementary Fig. 4e, f).
AdcaFoxO1 overexpression significantly increased lipid accumu-
lation in BSA/Oleate-treated NRVMs (Supplementary Fig. 4g). In
addition, FoxO1 knockdown using FoxO1-specific small interfer-
ing RNA (siRNA; siFoxO1) (Supplementary Fig. 4h) resulted in
less BSA/Oleate-induced lipid accumulation in NRVMs (Supple-
mentary Fig. 4i). Collectively, these findings reveal previously
unrecognized activation of FoxO1 in murine HFpEF and establish
its role in promoting lipid accumulation in cardiomyocytes.
Cardiomyocyte-specific FoxO1 deletion ameliorates the HFpEF
phenotype and diminishes cardiac steatosis. Based on the
association between FoxO1 downregulation and the cardiometa-
bolic protective effects observed in Xbp1s TG mice, we hypothe-
sized that FoxO1 activation in cardiomyocytes exerts a detrimental
action in HFpEF. To test this, we studied tamoxifen-inducible,
cardiomyocyte-specific FoxO1 knockout mice (cKO). FoxO1-cKO
mice and littermate controls (F/F) were exposed to HFpEF or
control diet for seven weeks (Fig. 3a). Both systolic and diastolic
LV performance were evaluated by non-invasive echocardio-
graphy. Systolic function measured as %LV ejection fraction
(LVEF%) was normal in all groups (Fig. 3b and Supplementary
Table 1). As expected, F/F mice exposed to HFpEF-inducing
conditions manifested increased early (E) wave to atrial (A) wave
ratio (E/A) on mitral pulse Doppler as well as increased ratios of E
wave to E’ wave on mitral tissue Doppler (E/E’), both indicative of
severe diastolic dysfunction (Fig. 3c–e and Supplementary
Table 1). Under HFpEF conditions, cKO mice exhibited sig-
nificantly improved diastolic function (Fig. 3c–e and Supple-
mentary Table 1) as well as improved exercise capacity (Fig. 3f)
and reduced pulmonary congestion (Fig. 3g), in the absence of
significant changes in cardiac hypertrophy (Supplementary
Fig. 5a, b). Importantly, cardiomyocyte-specific deletion of FoxO1
in HFpEF was associated with a reduction in myocardial neutral
lipid staining (Fig. 3h), triglyceride content (Fig. 3i), and nor-
malization of lipid gene expression (Fig. 3j). Examination of
mitochondrial substrate usage revealed a decrease in cardiac
pyruvate oxidation in HFpEF (Supplementary Fig. 6a) coupled
with an increase in protein levels of PDK4, a negative regulator of
pyruvate dehydrogenase (Supplementary Fig. 6b, c). Specificity of
the PDK4 protein band was confirmed using cardiac lysate from
cardiomyocyte-specific PDK4 transgenic mice (PDK4 TG)19. This
effect was independent of FoxO1. In addition, we observed a
reduction of cardiac fatty-acid oxidation in HFpEF coupled with a
trend toward an increase in lipid oxidation in FoxO1-cKO mice
(Supplementary Fig. 6d). In aggregate, these results point to global
amelioration of the HFpEF phenotype in cKO mice, supporting a
role for activation of FoxO1 in cardiomyocyte lipid accumulation
and development of HFpEF.
The E3 ubiquitin ligase STUB1 is a direct transcriptional target
of Xbp1s. Based on our findings unveiling the Xbp1s-FoxO1 axis
as a critical element of HFpEF pathogenesis, we next set out to
delineate mechanisms of Xbp1s-dependent FoxO1 degradation in
cardiomyocytes. Ubiquitin-dependent degradation of FoxO1 can
be mediated by multiple E3 ubiquitin ligases18. Surveying the
gene promoter regions of the ubiquitin ligases known to be
involved in FoxO1 degradation, we identified a conserved UPR
element (UPRE) nucleotide sequence—the prototypical binding
site of Xbp1s—in the promoter region of the E3 ubiquitin ligase
STUB1 (STIP1 homology and U-Box-containing protein 1)
(Fig. 4a). To pursue this, we engineered a luciferase reporter
vector harboring the UPRE of STUB1 (STUB1-Luc). Infection of
Fig. 1 Cardiomyocyte-specific overexpression of Xbp1s mitigates cardiac steatosis and induces FoxO1 protein degradation in HFpEF. a Representative
images of Oil Red O staining of left ventricular (LV) sections from wild-type (WT) and cardiomyocyte-restricted Xbp1s overexpressing (Xbp1s TG) HFpEF
mice. Scale bars= 50 μm. Images are representative of four hearts/group. b Cardiac triglyceride content in myocardial tissue from WT and Xbp1s TG
control (CTR) and HFpEF hearts (n= 4/group). c Representative immunoblot images of FoxO1 and GAPDH proteins from LV of WT and Xbp1s TG mice
under CTR and HFpEF conditions. Images are representative of three hearts/group. d Densitometric analysis of FoxO1 protein band. (n= 3/group).
e Representative immunoblot images of FoxO1 and GAPDH proteins from neonatal rat ventricular myocytes (NRVMs) transduced with adenovirus
expressing green fluorescent protein (GFP; AdGFP) or Xbp1s (AdXbp1s). Images are representative of four independent experiments. f Densitometric
analysis of FoxO1 protein band in the different experimental groups. (n= 4 biologically independent experiments). g Representative immunoblot images of
FoxO1, Lamin A/C, and GAPDH proteins in cytosolic and nuclear extracts from NRVMs transduced with AdGFP or AdXbp1s. Images are representative of
four independent experiments. h Densitometric analysis of cytosolic and nuclear FoxO1 protein band in the different experimental groups (n= 4
biologically independent experiments). i Representative immunoblot images of FoxO3, FoxO1, Xbp1s, and GAPDH proteins from NRVMs transduced with
AdGFP, AdXbp1s, or not transduced (−) in presence or absence of MG132. Arrow indicates FoxO3-specific band. Images are representative of five
independent experiments. j Densitometric analysis of FoxO1 protein band in the different experimental groups (n= 5 biologically independent
experiments). Results are presented as mean ± S.E.M. In b, d, and j, *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001, two-way ANOVA plus Sidak’s
multiple comparisons test. In f and h, *p < 0.05, unpaired, two-tailed Kolmogorov–Smirnov test.
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AdXbp1s in STUB1-Luc-transfected HEK293 cells resulted in
concentration-dependent induction of luciferase activity (Fig. 4b).
A similar increase in STUB1-luciferase activity was observed
when HEK293 cells and NRVMs were treated with the canonical
UPR activator tunicamycin (TUN) (Supplementary Fig. 7a, b).
Chromatin immunoprecipitation (ChIP) assay confirmed the
binding of Xbp1 to the STUB1 promoter (Fig. 4c, d). In addition,
pharmacological inhibition of IRE1α endoribonuclease activity
with MK-3946 or Xbp1s knockdown using Xbp1s-specific siRNA
abolished TUN-induced increases in STUB1-luciferase activity
(Supplementary Fig. 7a, b), confirming the specificity of the
Xbp1s-dependent increase in STUB1-luciferase activity.
To corroborate our findings, we infected NRVMs with AdXBP1s










































































































































Fig. 2 FoxO1 activation in hearts and cardiomyocytes from HFpEF mice. a Representative immunoblot images of FoxO1, Lamin A/C, and GAPDH proteins
in nuclear extracts from LV of CTR and HFpEF mice. Images are representative of six hearts/group. b Bar graphs depicting intensities of the nuclear FoxO1
protein band (n= 6/group). c Representative immunoblot images of FoxO1, Lamin A/C, and GAPDH proteins in nuclear extracts from adult mouse
ventricular myocytes (AMVMs) of CTR and HFpEF mice. Images are representative of six hearts/group. d Bar graphs depicting the nuclear FoxO1 protein
band intensities (n= 6/group). e mRNA levels of FoxO1, pdk4, and p21 in LV of CTR and HFpEF mice (n= 4/group). f mRNA levels of FoxO1, pdk4, and p21
in AMVMs of CTR and HFpEF mice (n= 8/group). Results are presented as mean ± S.E.M. In b, d, e, and f *p < 0.05, **p < 0.005, ***p < 0.0005, unpaired,
two-tailed Kolmogorov–Smirnov test.
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STUB1 mRNA (Fig. 4e and Supplementary Fig. 7c) and protein
(Fig. 4f, g) in an Xbp1s-dependent manner (Supplementary Fig. 7c);
similar findings were observed in XBP1s TG hearts (Fig. 4h, i).
Specificity of the putative STUB1 protein band in cardiomyocytes
was confirmed in NRVMs transfected with STUB1-specific siRNA.
Importantly, levels of STUB1 mRNA tracked with levels of Xbp1s
in vivo, with STUB1 transcript levels manifesting a significant
decrease in HFpEF hearts (Fig. 4j). Accordingly, under conditions
of HFD feeding in which Xbp1s is induced, STUB1 levels also
increase (Supplementary Fig. 7d) Collectively, these data provide
compelling evidence that STUB1 is a direct transcriptional target
of Xbp1s.
STUB1 regulates FoxO1 stability in cardiomyocytes. Our data
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proteolytic degradation of FoxO1. To examine this more directly,
we measured the impact of STUB1 on the half-life of FoxO1
protein. NRVMs were treated with cycloheximide to block pro-
tein translation, and steady-state levels of FoxO1 over the course
of 8 h were measured. Loss of STUB1 led to a significant decrease
in the early rate of decay of FoxO1 and increased the protein’s
half-life in this assay from ~4 h to almost 8 h. (Fig. 5a, b). In
support of this, overexpression of STUB1 in NRVMs using a
recombinant adenovirus driving expression of STUB1
(AdSTUB1), induced a decrease in FoxO1 protein levels coupled
with an increase in protein ubiquitination as compared with
AdGFP-infected control cells (Supplementary Fig. 8a, b). Cardi-
omyocyte infection with AdSTUB1 did not elicit changes in
FoxO1 mRNA levels as compared with AdGFP-infected cells
(Supplementary Fig. 8c). In aggregate, these results confirm that
STUB1 substantially participates in the regulation of FoxO1
protein stability in cardiomyocytes.
To delineate the role of STUB1 in Xbp1s-dependent control of
FoxO1 in cardiomyocytes, we evaluated FoxO1 mRNA and
protein levels in STUB1-depleted NRVMs in the setting of Xbp1s
overexpression. STUB1 knockdown in cardiomyocytes did not
affect FoxO1 transcript levels under basal conditions or after
Xbp1s overexpression (Fig. 5c). Strikingly, STUB1 depletion
significantly restored FoxO1 protein levels in AdXbp1s-infected
NRVMs (Fig. 5d, e). A similar pattern was observed using TUN
as an inducer of Xbp1s. TUN-treated NRVMs displayed a
reduction in FoxO1 protein, which was significantly reduced by
STUB1 knockdown (Supplementary Fig. 9a, b). Similar to our
observations with Xbp1s overexpression, TUN treatment in
NRVMs increased STUB1 mRNA levels (Supplementary Fig. 9c).
In addition, inhibition of Xbp1s splicing with MK-3946 was
sufficient to alleviate TUN-induced FoxO1 protein degradation,
confirming that TUN induces the reduction of FoxO1 protein
levels in an Xbp1s-dependent manner (Supplementary Fig. 9d, e).
Of note, neither TUN nor MK-3946 had any effects on FoxO1
mRNA levels in NRVMs (Supplementary Fig. 9f).
Finally, to further confirm the specificity of the Xbp1s–STUB1
interaction in the regulation of FoxO1 stability, we evaluated
another FoxO1 E3 ubiquitin ligase, SKP2 (S-Phase Kinase
Associated Protein 2)20. Whereas infection of NRVMs with
AdXBP1s resulted in increases in SKP2 mRNA (Supplementary
Fig. 10a), SKP2 knockdown using SKP2-specific siRNA (siSKP2)
did not relieve Xbp1s-dependent FoxO1 protein degradation
(Supplementary Fig. 10b). Similarly, neither autophagy activation
nor inhibition of intracellular proteases alleviated Xbp1s-
dependent FoxO1 protein degradation (Supplementary Fig. 10c)
Collectively, these data reveal that Xbp1s-dependent degradation
of FoxO1 protein in cardiomyocytes is, at least in part, dependent
on STUB1.
Discussion
The global spread of obesity and metabolic dysfunction, coupled
with widespread growth in hypertension, are altering the face of
cardiovascular disease, an evolution that is likely to continue to
accelerate. As a major part of this, HFpEF, a disorder devoid of
evidence-based therapy, is increasing in prevalence. Here, we
employed a clinically relevant murine model of cardiometabolic
HFpEF and made a series of novel mechanistic observations:
(1) Xbp1s, which is decreased in HFpEF9, reduces myocardial
lipid accumulation; (2) FoxO1 promotes lipid accumulation in
HFpEF cardiomyocytes; (3) Xbp1s promotes FoxO1 protein
degradation; (4) cardiomyocyte-specific deletion of FoxO1 ame-
liorates the HFpEF phenotype and diminishes cardiac steatosis;
(5) the E3 ubiquitin ligase STUB1, a direct transcriptional target
of Xbp1s, is also downregulated in HFpEF and governs
FoxO1 stability in cardiomyocytes. In aggregate, we unveil the
role of FoxO1 as a driver of lipid accumulation in cardiomyo-
cytes, functioning under the control of its molecular brake,
Xbp1s, and emerging as a critical contributor to HFpEF patho-
genesis. We propose a novel pathophysiological model of HFpEF
in which suppression of the Xbp1s arm of the UPR blunts STUB1
expression, leading to the stabilization and overactivation of
FoxO1 in cardiomyocytes with consequent cardiomyocyte stea-
tosis and associated detrimental sequelae (Fig. 6).
Obesity and diabetes significantly increase the risk of athero-
sclerotic coronary artery disease and myocardial infarction, which
almost inevitably impairs systolic function leading to HFrEF.
However, obese people are at markedly increased risk of HFpEF
independent of the occurrence of ischemic cardiac injury21,22.
Indeed, metabolic disorder-related HFpEF is the most prevalent
phenotype of HFpEF in the community3,23. Prior work has
described fatty infiltration of cardiomyocytes in failing hearts,
causally linking cardiac lipid overload with systolic and diastolic
dysfunction24–26. Thus, HFpEF can be considered the most
common clinical manifestation of lipotoxic cardiomyopathy.
It is important to note that HFpEF, both clinically and
mechanistically, does not completely overlap with obesity, and that
obesity is one—the most common—of the many comorbidities
shaping the complexity of the pathophysiological mechanisms of
HFpEF. Accordingly, in obese (HFD-fed) mice, we observed acti-
vation, rather than suppression, of Xbp1s9,10 and STUB1, coupled
with activation of FoxO1, suggesting a feedback circuit whereby
Xbp1s acts to increase transcription of STUB1 to blunt the persistent
activation of FoxO1 observed under HFD conditions. Conversely, in
HFpEF hearts, downregulation of Xbp1s leads to suppression of
STUB1 transcription, further increasing FoxO1 activation and
increasing cardiomyocyte lipid accumulation. Therefore, as obesity
alone does not elicit HFpEF, the mechanistic underpinnings of
obesity-induced cardiomyopathy are different from those in HFpEF,
Fig. 3 Cardiomyocyte-restricted deletion of FoxO1 improves HFpEF phenotype in mice and reduces cardiac lipid accumulation. a Experimental design.
FoxO1 flox/flox (FoxO1 F/F) and FoxO1 flox/flox/α-MHC-MerCreMer mice (FoxO1 F/F MCM; cKO) were injected once a day for 5 consecutive days. After
15 days, FoxO1 F/F and FoxO1-cKO were exposed to CTR or HFpEF combination diet (blue triangle). After 7 weeks, mice were subjected to functional
analysis and tissue harvesting (red empty triangle). b Left ventricular ejection fraction % (LVEF%) of different experimental groups (n= 4 for F/F CTR, F/F
cKO, and F/F HFpEF groups; n= 5 for cKO HFpEF group). c Representative pulse wave Doppler (top) and tissue Doppler (bottom) tracings from different
experimental groups. Images are representative of four hearts/group. d E/A ratio of different experimental cohorts (n= 4 for F/F CTR, F/F cKO, and F/F
HFpEF groups; n= 5 for cKO HFpEF group). e E/E’ ratio of different experimental cohorts (n= 4 for F/F CTR, F/F cKO and F/F HFpEF groups; n= 5 for cKO
HFpEF group). f Running distance during exercise exhaustion test (n= 4 for F/F CTR, F/F cKO, and F/F HFpEF groups; n= 5 for cKO HFpEF group). g Ratio
between lung weight (LW) immediately after mouse euthanasia (wet) and tibia length (LW/TL) (n= 4 for F/F cKO and F/F HFpEF groups; n= 5 for F/F
CTR and cKO HFpEF groups). h Representative images of Oil Red O staining of LV sections from FoxO1 F/F and FoxO1-cKO HFpEF hearts. Scale bars=
50 μm. Images are representative of four hearts/group. i Cardiac triglyceride content in myocardial tissue from FoxO1 F/F and FoxO1-cKO HFpEF hearts
(n= 4/group). j mRNA levels of SREBP1 and FASN in LV of FoxO1 F/F and FoxO1-cKO CTR and HFpEF hearts (n= 6 for F/F CTR, F/F HFpEF, and cKO
HFpEF groups; n= 5 for cKO CTR group). Results are presented as mean ± S.E.M. In b, d–g, j *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001, two-
way ANOVA plus Sidak’s multiple comparisons test. i ****p < 0.0001, unpaired, two-tailed Kolmogorov–Smirnov test.
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supporting a model in which FoxO1 overactivation in HFpEF leads
to the detrimental functional consequences of cardiomyocyte lipid
accumulation.
The precise mechanisms whereby lipids induce cardiac dys-
function are unclear. In principle, pathological lipid accumula-
tion in cardiomyocytes can result from increased FA uptake/
biogenesis, decreased FA oxidation, or a combination of the two.
In the hearts of obese humans and rodents, an increase, rather
than a decrease, in FA oxidation has been reported27,28. Con-
versely, impaired FA oxidation is a hallmark of metabolic dys-
function in HF. In patients with HFrEF without metabolic
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Fig. 4 STUB1 is a direct transcriptional target of Xbp1s. a Conserved consensus sequence of Xbp1s-binding site (unfolded protein response element—
UPRE) in the promoter region of STUB1. 129 bp from the transcriptional start site (arrow). b Luciferase (Luc) activity in human embryonic kidney 293 cells
(HEK293) transfected with STUB1-luciferase reporter construct (STUB1-Luc) and transduced with the increasing multiplicity of infection of AdGFP or
AdXbp1s (n= 6 biologically independent experiments). c Electrophoretic analysis of chromatin immunoprecipitation (ChIP) assay of STUB1 promoter in
NRVMs transduced with AdGFP or AdXbp1s. ChIP was performed with either control mouse immunoglobulin G (IgG) or anti-Xbp1s antibody. PCR was
conducted with primers spanning the UPRE site. Images are representative of 4 independent experiments. d Densitometric analysis of STUB1 ChIP band
intensities in the different experimental groups (n= 4 biologically independent experiments). e mRNA level of STUB1 in NRVMs transfected with STUB1-
specific small interfering RNA (siSTUB1) or scrambled siRNA control and transduced with AdGFP or AdXbp1s (n= 4 biologically independent
experiments). f Representative immunoblot images of Xbp1s, STUB1 and GAPDH proteins from NRVMs transfected with siSTUB1 or scrambled siRNA
control and transduced with increasing multiplicity of infection of AdGFP or AdXbp1s. Images are representative of five independent experiments.
g Densitometric analysis of STUB1 protein band in the different experimental groups (n= 5 biologically independent experiments). h Representative
immunoblot images of Xbp1s, STUB1, and GAPDH proteins from LV of WT and Xbp1s TG mice. High and low exposure (high/low exp). Images are
representative of six hearts/group. i Bar graphs depicting STUB1 protein band intensities in WT and Xbp1s TG LV samples (n= 6/group). j mRNA level
of XBP1s and STUB1 in LV of CTR and HFpEF hearts (n= 4 for Xbp1s CTR group; n= 6 for the remaining groups). Results are presented as mean ± S.E.M.
In b and e, *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001, one-way ANOVA plus Sidak’s multiple comparisons test. In d, g, i, j **p < 0.005, ****p <
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Fig. 5 STUB1 mediates Xbp1s-dependent FoxO1 protein degradation. a Representative immunoblot images of FoxO1, STUB1, and GAPDH proteins from
NRVMs transfected with siSTUB1 or scrambled siRNA control and treated with cycloheximide (CHX) for different durations (0, 1, 4, and 8 h). Images are
representative of five independent experiments. b Densitometric analysis of FoxO1 protein band in the different experimental groups. (n= 5 biologically
independent experiments). c mRNA level of FoxO1 in NRVMs transfected with siSTUB1 or scrambled siRNA control and transduced with AdGFP or
AdXbp1s (n= 4 biologically independent experiments). d Representative immunoblot images of FoxO1, Xbp1s, STUB1, and GAPDH proteins from NRVMs
transfected with siSTUB1 or scrambled siRNA control and transduced with AdGFP, AdXbp1s. Images are representative of four independent experiments.
e Densitometric analysis of FoxO1 protein band in the different experimental groups. (n= 4 biologically independent experiments). Results are presented
as mean ± S.E.M. In b, c, and e *p < 0.05, **p < 0.005, ****p < 0.0001, two-way ANOVA plus Sidak’s multiple comparisons test.
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in myocardial triglyceride content has been observed25. Con-
versely, in obese/diabetic patients with HFrEF, significant
accumulation of intramyocardial lipid has been reported25.
These data suggest that impaired FA oxidation alone is insuf-
ficient to elicit significant myocardial steatosis, and cardiac lipid
overload is largely a function of increased FA uptake/biogenesis.
Indeed, although increased FA oxidation has long been con-
sidered a culprit contributing to cardiac dysfunction in obese
models, recent data suggest that increased FA oxidation does not
cause cardiac dysfunction in mice29,30. Taken together, these
observations suggest that cardiac lipotoxicity is not attributable
to increased fatty-acid oxidation per se, but rather to an
imbalance of fatty-acid supply, storage, and use. Consistent with
this, we have observed an increase in cardiac lipogenic signature
coupled with reduction in mitochondrial FA oxidation in car-
diometabolic HFpEF. Similarly, in two models of reduced car-
diac lipid accumulation in HFpEF (Xbp1 overexpression and
FoxO1 deletion) we did not observe an increase in FA oxidation
in cardiomyocytes, suggesting that the prevalent mechanisms of
lipid accumulation in HFpEF cardiomyocytes are activation of
FA uptake/biogenesis pathways.
Dysregulation of the UPR pathway has emerged as a hallmark of
cardiac alterations in HFpEF31,32. We have previously demon-
strated, in both clinical and experimental HFpEF, inflammation-
dependent suppression of the IRE1α/Xbp1s arm of the UPR9.
Restoration of Xbp1s levels in failing cardiomyocytes results in
diminished diastolic dysfunction and amelioration of the global
HFpEF phenotype9. Here, we have unveiled proteasomal degra-
dation of FoxO1 as a major mechanism of Xbp1s-dependent car-
dioprotective effects in HFpEF.
The interplay between the UPR and lipid biology is complex.
FA can activate the UPR, and specific branches of the UPR reg-
ulate lipid metabolism33. For example, in hepatocytes, Xbp1s
regulates lipogenesis34,35, a function that is independent of its
classical role in ER stress and critically involves FoxO115. With
respect to cardiac biology, FoxO1 participates in remodeling,
autophagy, apoptosis, responses to oxidative stress, and
regulation of metabolism16,36,37. In addition, FoxO1 has emerged
as an important target of insulin and other growth factors in the
myocardium16, and we have reported that FoxO1 is persistently
activated in cardiac tissue from murine models of long-term
diabetes17. Despite this, upstream regulators of FoxO1-dependent
regulation of lipid homeostasis in cardiomyocytes remain largely
unknown, and a role of FoxO1 in HFpEF has not been reported
previously.
Xbp1s is a powerful transcription factor acting through a variety
of transcriptional targets involved in many fundamental cellular
responses to stress. We report here that the E3 ubiquitin ligase
STUB1 is a direct downstream target of Xbp1s. STUB1 is a major
FoxO1 ubiquitin ligase driving its proteasomal degradation38.
However, whereas we observed STUB1-dependence of FoxO1
protein degradation upon Xbp1s activation, we recognize that this
may not be the only mechanism involved in FoxO1 degradation
upon metabolic stress in cardiomyocytes; other mechanisms may
play a role. STUB1, also known as carboxyl terminus of Hsc70-
interacting protein (ChIP), is a dual function co-chaperone/ubi-
quitin ligase that is highly expressed in the heart and vasculature39.
Interestingly, a cardioprotective role of STUB1 involving, at least in
part, the modulation of lipid accumulation, has been observed in
two models of HFrEF, suggesting a central role of STUB1 in car-
diomyocyte homeostasis40,41. Direct targeting of transcription
factors for therapeutic purposes has proven challenging42. There-
fore, the identification of negative upstream regulators of
FoxO1 such as STUB1 might result in valuable therapeutic targets
to diminish FoxO1 activation and its negative metabolic con-
sequences. Indeed, strategies aiming to enhance STUB1 function-
ality for therapeutic applications in cardiovascular disease have
been proposed recently43, supporting the potential feasibility of
targeting STUB1 for clinical gain.
We have demonstrated that FoxO1 suppression in HFpEF is
beneficial. Interestingly, these beneficial effects occur in the
absence of a significant reduction in cardiac hypertrophy. By
contrast, we recently described a pro-hypertrophic role for FoxO1
















Fig. 6 Proposed model. Schematic depicting a mechanistic model of Xbp1s-STUB1-FoxO1 axis in HFpEF.
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Together, these data suggest that FoxO1 plays different roles in
cardiac pathology depending on the specific stress conditions.
Another major metabolic abnormality observed in HF is sys-
temic insulin resistance. HF causes insulin resistance44 and insulin
resistance worsens HF, a feedback regulatory circuit contributing
to HF susceptibility and progression. We and others have posi-
tioned FoxO1 as a pivotal element in the control of insulin sig-
naling in the heart. Forced expression of FoxO1 in cardiomyocytes
culminates in reduced insulin sensitivity and impaired glucose
metabolism16. In HFpEF hearts, we observe increased activity of
PDK4, which will repress glucose oxidation45. Indeed, an increase
in PDK4 levels is a common feature of hearts subjected to
metabolic stress. Interestingly, in cardiometabolic HFpEF the
increase in PDK4 is independent of FoxO1.
Beyond glucose metabolism, less well-known is the role of
FoxO1 in regulating cardiac lipid homeostasis. FoxO1 nuclear
compartmentalization and enhancement of its transcriptional
activity, together with increases in FA uptake, have been observed
in models of long-term diabetes and obesity46,47. Despite this,
debate regarding the functional consequences of persistent dia-
betes or obesity on cardiac function persists, with some reporting
little or no effect48,49 and others reporting evolution toward
HFrEF26,50. Here, we have provided the clinical context—the
syndrome of HFpEF—in which FoxO1 overactivation promotes
cardiac lipotoxicity. We observed impaired cardiac mitochondrial
FA oxidation in HFpEF. Interestingly, in FoxO1-cKO mice sub-
jected to HFpEF, we observed a trend toward amelioration of
mitochondrial fatty-acid oxidation in the absence of changes in
glucose oxidation. Collectively, these results imply that a major
disruption of energetic substrate utilization occurs in HFpEF, and
the downregulation of FoxO1 tends to mitigate this energetic
disturbance, acting through a decrease in HFpEF-induced
lipotoxicity.
It is important to note that cardiometabolic alterations in
HFpEF, and their underlying pathophysiological mechanisms,
exhibit a certain degree of sex dependence. Female mice seem to
be protected from experimental HFpEF10, whereas some evidence
suggests a predilection for HFpEF in women3,51. Despite this,
sexual dimorphism in HFpEF pathophysiology is an under-
developed area of investigation. Therefore, elucidation of sex-
neutral signaling pathways involved in HFpEF pathogenesis is
warranted.
Here, we have unveiled an Xbp1s-FoxO1 signaling circuit in
diseased cardiomyocytes, thereby defining events downstream of
the UPR in heart that govern metabolic events. We have identi-
fied a biological axis, Xbp1s-STUB1-FoxO1, in the regulation of
cardiac steatosis in HFpEF, providing a novel pathophysiological
model for cardiometabolic HFpEF. The field of experimental
HFpEF is rapidly moving from a simplistic view in which HFpEF
equals diastolic dysfunction to a view of HFpEF as a complex
syndrome in which metabolic alterations contribute importantly
to its pathogenesis. As such, delineation of alterations in lipid
metabolism and their consequences on cardiac function is of
paramount importance in deciphering mechanisms underlying
this prevalent and devastating syndrome.
Methods
Experimental animals. All experiments involving animals conformed to the Guide
for the Care and Use of Laboratory Animals published by the US National Insti-
tutes of Health (NIH Publication 8th edition, update 2011) and were approved by
the Institutional Animal Care and Use Committee of the University of Texas
Southwestern Medical Center. All studies were in compliance with all ethical
regulations. C57BL/6 N mice were used for wild-type (WT) studies. Tetracycline
responsive elements (TRE)-Xbp1s mice were crossed with mice harboring a tet-
racycline transactivator (tTA) transcription factor driven by α-myosin heavy chain
promoter (αMHC-tTA) to generate mice with cardiomyocyte-specific inducible
overexpression of Xbp1s (Xbp1s TG)9,52. Cardiomyocyte-specific FoxO1 knockout
(cKO) animals, mice harboring a floxed FoxO1 allele were crossed with α-MHC-
MerCreMer transgenic mice. FoxO1-cKO and corresponding control floxed or
α-MHC-MerCreMer mice were maintained on an FVB genetic background. Male
adult (10/12-week-old) mice were used in the experiments. Mice were maintained
on a 12-hour light/dark cycle from 6 AM to 6 PM, 65–75 °F, 40–50% humidity and
had unrestricted access to food (#2916, Teklad for CHOW groups and #D12492,
Research Diet Inc. for the HFD groups) and water. N[w]-nitro-l-arginine methyl
ester (L-NAME; 0.5 g/L, Sigma-Aldrich) was supplied in the drinking water or
embedded in the chow (custom made #D16082402, Research Diet Inc). HFpEF was
induced by feeding mice with HFD+ L-NAME diet from 5 to 15 weeks9,10.
Pregnant Sprague-Dawley rats were purchased (Charles River Laboratories) and
were used for the sole purpose of harvesting primary cardiomyocytes from 1–2-day
old rat pups.
Conventional echocardiography and Doppler imaging. Transthoracic echo-
cardiography was performed using a VisualSonics Vevo 2100 system equipped with
MS400 transducer (Visual Sonics Inc). Indices of systolic function were obtained in
conscious, gently restrained mice from M-mode scans at midventricular level.
Indices of diastolic function were obtained in anesthetized mice from apical four-
chamber view using pulsed-wave and tissue Doppler imaging. Anesthesia was
induced by 5% isoflurane and, during echocardiogram acquisition, isoflurane was
reduced to 1.0–1.5% and adjusted to maintain a heart rate >400 beats per min9,10.
All parameters were measured at least 3 times, and averages are presented.
Exercise exhaustion test. Exercise tests were performed as depicted in the figures
using the following protocol. After acclimatization, mice ran uphill (20°) on a
treadmill apparatus (Columbus Instruments) according to a ramping speed
protocol9,10 until exhaustion. Exhaustion was defined as the inability of the mouse
to return to running within 10 s of direct contact with an electric-stimulus grid.
Histology and myocardial lipid measurements. Hearts were harvested and flash
frozen in an embedding medium containing a 3:1 mixture of Tissue Freezing
Medium (Triangle Biomedical Sciences, Durham, NC) and gum tragacanth (Sigma,
St. Louis, MO). 0.3% Oil Red O (BDH, Poole, United Kingdom) staining was
performed on 5 μm-thick sections according to standard procedures53. Cardiac
sections were visualized with a Leica DM2000 upright photomicroscope. Total
triglyceride content was determined biochemically from myocardial tissue collected
immediately after euthanasia. Colorimetric quantification of total triglycerides was
performed using Triglycerides Reagent—Thermo Fisher Scientific according to the
manufacturer’s instructions17,54.
Cardiomyocyte isolation, treatment, transfection, and adenovirus production,
and transduction. AMVMs were isolated from littermates of each experimental
group as follows9. Hearts were dissected and immediately digested by retrograde
perfusion with perfusion buffer (113 mM NaCl, 4.7 mM KCl, 0.6 mM KH2PO4,
0.6 mM Na2HPO4, 1.2 mM MgSO4, 10 mM HEPES, 12 mM NaHCO3, 10 mM
KHC03, 30 mM taurine, 10 mM butanedione monoxime, and 5.5 mM glucose) for
1 min followed by buffer containing liberase TM (0.025 mgmL−1, Roche) and
trypsin (0.025%) for 14 min. The left ventricle was dissected and minced in a
perfusion medium supplemented with 10% dialyzed fetal bovine serum. After fil-
tration, AMVMs were allowed to sediment by gravity and non-cardiomyocytes
were discarded. Calcium reintroduction was performed stepwise from 0 to 1.8 mM
in six steps. AMVMs were stained with LipidTOX deep red (1:200 dilution; Invi-
trogen) for 1 h according to the manufacturer’s instructions. Images were obtained
using a Zeiss LSM 880 upright confocal fluorescence microscope. NRVMs were
isolated from 1 to 2-day-old Sprague-Dawley rats9. NRVMs were cultured in
Dulbecco’s modified Eagle’s medium/M199 (3:1) containing 3% fetal bovine serum
and antibiotics before performing the experiments. NRVMs were treated in serum-
free medium with BSA/oleic acid complexes (Sigma-Aldrich, O3008-5ML, 2 moles
of oleic acid per 1 mole of BSA) at the concentration of 200 μM for 3 h, 6 h, 24 h or
48 h. Free fatty-acid BSA (Sigma-Aldrich, A8806-5G) was used as control. Neutral
lipids were visualized by Oil O Red staining as described above. For gene knock-
down, NRVMs were transfected with three sequence-independent, STUB1-,
FoxO1-, and siSKP2 (Mission, Sigma-Aldrich) using Lipofectamine RNAiMax
(Invitrogen) in Opti-MEM (Gibco). After 6 h, cells were washed twice with growth
medium and culture overnight in growth medium. For adenovirus-mediated
protein overexpression, cells were transduced for 6 h with AdXBP1s52,
AdcaFoxO137, and AdSTUB1 adenoviruses with increasing multiplicity of infection
(MOI) of virus, and cells were harvested 24-hour post-infection. A GFP adenovirus
(AdGFP) construct was used as control at the same MOI. Human STUB1 cDNA
was obtained from UT Southwestern Center for Human Genetics and subcloned
into an adenovirus expression vector using Adeno-X Adenoviral System 3 (Takara)
following the manufacturer’s instructions. Adeno-X 293 cell line was purchased
from Clontech (Adeno-X 293 Cell Line, 632271). When appropriate, NRVMs and
HEK293 cells were treated with MG132 (Sigma-Aldrich, 10μM; 4 h), bafilomycin
A1 (LC Laboratories, 50 nM; 2 h), cell-permeable protease inhibitor cocktail
(Sigma-Aldrich, 1:200 dilution; 2 h), TUN (Sigma-Aldrich, 10 μg/mL; 24 h), MK-
3946 (Tocris, 10 μM, 24 h), cycloheximide (Sigma-Aldrich, 5 μg/mL, 1–8 h).
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Lactate dehydrogenase (LDH) assay. To evaluate cell survival, LDH release was
quantified using the CytoTox96 cytotoxicity kit (Promega) according to the
manufacturer’s instructions. Each experiment was performed in three biological
replicates each time in triplicate. LDH release was calculated as follows: (medium
LDH)/(medium LDH+ intracellular LDH).
Protein extracts, subcellular fractionation, and immunoblot analysis. Whole
protein extracts from frozen mouse hearts, AMVMs and NRVMs were prepared by
lysis in ice-cold modified radio immunoprecipitation assay (RIPA) buffer (150 mM
NaCl, 50 mM Tris HCl pH 7.4, 1% Triton-X 100, 0.5% sodium deoxycholate, 0.1%
SDS, 5 mM ethylenediaminetetraacetic acid (EDTA), 2 mM EDTA) containing
protease and phosphatase inhibitors. Nuclear and cytosolic extracts were prepared
using the NE-PER™ Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific)
following the manufacturer’s instructions. Proteins were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis on 4–20% gradient gels (Bio-
Rad) and transferred to nitrocellulose membranes. An Odyssey scanner (LI-COR
version 3.0) was used as detection system. The separation between the nuclear and
cytosolic fractions was verified by blotting for the cytosolic protein GAPDH and
the nuclear membrane protein Lamin A/C. Tandem ubiquitin binding entities for
the detection of ubiquitinated protein were used according to the manufacturer’s
instructions (Life Sensors). Proteins were detected with a 1000-fold dilution of the
following primary antibodies: FoxO1 (#2880, Cell Signaling); FoxO3 (#2497, Cell
Signaling); Xbp1s (poly6195, BioLegend); GFP (AB10145, Sigma-Aldrich); STUB1
(#2080, Cell Signaling); Ubiquitin (#3933, Cell Signaling); LC3 (previously
developed55); Lamin A/C (05-714, Sigma-Aldrich); PDK4 (previously
developed56), OXPHOS cocktail (ab110413, Abcam). 10,000-fold dilution of
GAPDH (10R-G109a, Fitzgerald). Uncropped scans of immunoblot images are
available in the Supplementary Information.
RNA isolation and qPCR. Total RNA was extracted from murine hearts, AMVMs,
or NRVMs using TRIzol reagent or Quick-RNA™ MicroPrep kit (Zymo Research).
A total of 500 ng RNA was used for reverse transcription using iScript reagent (Bio-
Rad). qPCR reactions were performed in triplicate with SYBR master mix (Bio-
Rad). The 2−ΔΔCT relative quantification method, using 18 S for normalization,
was used to estimate the amount of target mRNA in samples, and fold ratios were
calculated relative to mRNA expression levels from control samples. qPCR primer
sequences are provided in Supplementary Table 2.
Analysis of mitochondrial respiratory function in hearts and cardiomyocytes.
NRMVs were transduced with AdGFP and AdXbp1s as described above. Cardiac
mitochondria were isolated by ultracentrifugation in ice-cold isolation buffer (210
mM MOPS, 70mM mannitol, 10mM sucrose, 1 mM EDTA, pH= 7.4). Oxygen
consumption was measured using a fluorescence-based oxygen sensor (NeoFox,
Ocean Optic) connected to a phase measurement system from the same company.
The sensor was calibrated according to the manufacturer’s instructions57. NRVM cell
numbers were counted using a hemocytometer. In brief, 1 × 104 cardiomyocytes were
incubated in a solution containing KMES 60mM, MgCl 223mM, KH2PO4 10mM,
Hepes 20mM, taurine 20mM, mannitol 110mM, EGTA 0.5mM, and DTT 0.3mM
(pH 7.1) at 4 °C, and permeabilized with saponin (50 ng/mL) for 5 min before
substrates were added. Isolated mitochondria from hearts (0.25 mg/mL) were incu-
bated with the following buffer: 210mM MOPS, 70mM mannitol,10mM sucrose,
5 mM KH2PO4, pH= 7.458. To measure complex I mediated OCR, glutamate
(10mM) and malate (5mM) were added. State3 respiration was activated by adding
ADP (2.5mM), whereas state 4 respiration was measured after adding oligomycin
(1 μM). For complex II-mediated OCR, 5mM succinate was added. For the mea-
suring of palmitoyl/carnitine-mediated OCR, 25 μM palmitoyl-carnitine was added
to each experiment.
Luciferase and chIP assays. Transcriptional assays using pDR4, a luciferase
vector harboring two STUB1-UPREs in the presence of AdXbp1s or AdGFP
control were performed in HEK293 (Clontech; cat# 632271) and NRVMs37. The
luciferase vector was transfected into HEK293 cells using Fugene HD (Roche) and
into NRVMs using Lipofectamine 3000 (Thermo-Fisher). Luciferase activity was
measured using a dual-luciferase kit (Promega) and normalized to renilla activity.
Quantitative analyses of ChIP assays were conducted to assess Xbp1s occupancy at
the STUB1 promoter using the Zymo-Spin ChIP kit according to the manu-
facturer’s instructions (Epigenetics). In brief, AdGFP- and AdXbp1s-infected
NRVMs were exposed to 1% formaldehyde with gentle shaking (15 min, room
temperature). After quenching the cross-linking reaction with glycine, cells were
washed twice with PBS, and then homogenized in nuclear extraction buffer. The
homogenate was centrifuged (10 min, 500 × g, 4 °C) and the supernatant was dis-
carded. The nuclear pellet was resuspended in nuclear lysis buffer, sonicated, and
centrifuged (15 min, 12,000 × g, 4 °C) to prepare chromatin solution. Chromatin
solution was diluted 10-fold and incubated with control (IgG) and Xbp1s antibody
overnight at 4 °C with rotation. DNA purified from chromatin solutions was used
as input. Purified DNA with or without immunoprecipitation was used to deter-
mine relative Xbp1s occupancy by comparing the Ct value of 10-fold diluted input
DNA with undiluted immunoprecipitated DNA samples in control (IgG) and
Xbp1s antibody. Primers used were (forward, reverse):
GGCGGAGCCTTGGTCTGA, CGATCCGCCACCGGAACT).
Statistical analysis. Results are presented as mean ± SEMM. Differences were
analyzed by two-tailed unpaired Kolmogorov–Smirnov test for experiments with
two groups and one-way or two-way analysis of variance plus Sidak’s or Tukey’s
post hoc test for multiple comparisons as appropriate in experiments including ≥3
groups. A minimum value of p < 0.05 was considered statistically significant. All
experiments were performed with at least three biological replicates. Statistical
analyses were conducted using GraphPad Prism software 8.0. No statistical analysis
was used to predetermine sample sizes; estimates were made based on our previous
experience, experimental approach, availability, and feasibility required to obtain
statistically significant results. Experimental animals were randomly assigned to
each experimental/control group. Investigators were blinded to the genotypes of
the individual animals during the experiments.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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